SMARCA1 and epithelioid sarcoma: Given synthetic lethality between the loss of the SWI/SNF component-encoding gene SMARCB1 in epithelioid sarcoma and EZH2 inhibition with the now FDA-approved drug tazemetostat, EZH2 inhibition may represent a future therapeutic strategy in uterine adenosarcoma45.